The report produced by the Expert Advisory Group on Cancer (EAGC; chaired by the Chief Medical Officer (CMO) offers a clear policy framework. It sets out principles to shape the way services are developed. It seeks to achieve consistency in the delivery of cancer services across England and Wales through the adoption of a common structure based on three key elements: primary care: cancer units: and cancer centres. Implementation of this policy is envisaged as a devolved process. with much of the important detail to be worked out on a local basis.
The National Health Service (NTHS) Executive has endorsed the policy after only minor modifications to the consultative text. although their approach to issues such as resources. timescales. and priority are yet to be clarified. Important questions of manpower supply and training are also in urgent need of clear direction. Some of the underlying issues which the policy sought to address are of immediate concern. and in many parts of the country the 'Calman' approach is beginning to be adopted. Many of the regions have established working parties to take thinking forward in advance of a formal obligation to do so. This is a gratifying response to a consultation document and implies recognition of the weaknesses in cancer services which the CMO set out to address. These early moves to consider the adoption of the approach have exposed uncertainties about how it can best be implemented. The However, both the complexities of management and the nature of treatment needs for many of these cancer sites suggests that some limitations should be accepted by units in the extent of their clinical roles, reflecting working agreements as to which cases ought to be referred to the cancer centre. Taking carcinoma of the pancreas as an example. there is a proportion. perhaps as high as 20% of cases, in which early diagnosis leading to potentially curative surgery may be possible. In ovarian cancer. management is frequently concerned with the selection and delivery of an appropriate sequence of chemotherapy. tailored to the status of the patient and stage of the tumour. These issues exemplify clinical policy issues that need debate if appropriate distinctions are to be made between unit and centre roles.
Cancer centres. and exceptionally for one or two of these cancer sites some of the largest units. should expect to deal with all or most of the following: bone, central nervous system, head and neck, primary liver tumours, oesophagus, soft tissue sarcomas, germ cell tumours. childhood and adolescent cancers, plus rare and complex diseases. Gesophagus excepted, these cancers occur in small numbers below a threshold of 8 new cases per 100 000 population per year. The perhaps controversial case for putting oesophageal cancer in the cancer centre/largest unit group reflects a current pattern of widely distributed and variable practice. with generally poor results. Disentangling these issues will become clearer as considered professional guidance becomes available from interested multidisciplinary groups. colleges and professional bodies.
What is needed to establish the cancer unit?
The key to successful progress lies in dialogue between the principal parties. a process which has already begun in many places, albeit tentatively. Those who must be involved are the DHAs as a focus for purchaser perspectives within fundholding. as well as representing their statutory roles. trust management and relevant clinicians. The latter need to be drawn into these discussions because their experience is essential if site-specific services are to be addressed. These discussions will address a number of matters:
(1) The range of cancer sites requiring consideration: (2) Realistic options for service delivery and clinical organisation for each: (3) The necessary expertise skills that are required and how shortfalls might be addressed: (4) 'Whole hospital' cancer issues and how these are to be resolved; (5) The impact of greater specialisation in cancer treatment on the delivery of other services; (6) Facilities and accommodation necessary to provide the services; (7) Cost and timetable implications. These issues emphasise the definition of a cancer unit which presupposes that there will be an agreed but finite period during which an existing hospital or group of hospitals develop their service to achieve the desired level of performance. Once discussions covering these issues have been satisfactorily completed, and agreed criteria satisfied, then a process is required which will allow the parties concerned to secure the designation of their cancer unit. This process of designation ought to be based primarily on agreement E aishi-cancer units RA Haward x 533 between DHAs and the trusts concerned. Exceptionally it may need to be resolved within a wider context, perhaps through involvement of the regional tier. For a cancer unit to be designated six important questions will need to have been answered:
( Effective cancer registries are an essential prerequisite for comparative audits on a large scale. There are also moves being made by those interested in some cancer sites to press the merits of obligatory national audit, quality assurance. and even accreditation of site-specific unit services.
The final element is entry into clinical trials. Trials provide a means of quality assurance of those aspects of the treatment and care covered by the trial protocols. Entry is generally associated with good outcomes (Stiller. 1994) . Monitoring the range of trials into which patients are entered and the proportion of eligible patients included is a valid measure of performance.
Checklists for action
It is worth summarising in checklist form the main issues which units need to consider, covering key roles and the principle changes which need to be brought about. 
